What Happens: Improved insulin sensitivity Better fat metabolism Reduced inflammation Positive effects on lipid profiles Lower blood pressure Cardiovascular benefits What You Experience: More energy Better exercise tolerance Improved lab markers (cholesterol, triglycerides) Reduced risk of metabolic diseases These effects contribute to overall health improvement beyond just weight loss
We also assess the potential mechanisms that contribute to the reduction in major adverse cardiovascular events in individuals treated with GLP1R agonists and highlight the emerging cardiovascular biology of novel GLP1-based multi-agonists currently in development
Building on these research findings, Eli Lilly developed a dual agonist targeting GLP-1R/GIPR, called tirzepatide, which was approved by the FDA in 2022 and showed promising therapeutic effects for T2D and obesity
Underlying health conditions, such as hypothyroidism or PCOS, may slow your progress and are worth discussing with a licensed healthcare provider
Your provider will review your responses Complete your medical intake and a Zealthy provider will get back to you about treatment options, such as semaglutide